Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 15/20 | 0.66 |
| ▸ | MAPK13 | O15264 | 13/20 | 0.66 |
| ▸ | MAPK12 | P53778 | 13/20 | 0.66 |
| ▸ | MAPK11 | Q15759 | 13/20 | 0.66 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.42 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | RPA1 | P27694 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2201071 | 0.92 | MAPK13 (0.53) | MAPK14MAPK13MAPK12MAPK11HDAC1 | |
| SCHEMBL2198645 | 0.88 | MAPK14 (0.66) | MAPK14MAPK13MAPK12MAPK11HDAC3 | |
| SCHEMBL2197537 | 0.86 | MAPK13 (0.53) | MAPK14MAPK13MAPK12MAPK11HPGD | |
| SCHEMBL2200936 | 0.83 | MAPK14 (0.64) | MAPK14MAPK13MAPK12MAPK11HDAC3 | |
| SCHEMBL6396535 | 0.83 | MAPK14 (0.78) | MAPK14MAPK13MAPK12MAPK11HPGD | |
| SCHEMBL2202867 | 0.83 | MAPK14 (0.56) | MAPK14MAPK13MAPK12MAPK11POLB | |
| SCHEMBL2198608 | 0.83 | MAPK14 (0.64) | MAPK14MAPK13MAPK12MAPK11POLB | |
| SCHEMBL6401051 | 0.83 | MAPK14 (0.78) | MAPK14MAPK13MAPK12MAPK11HPGD | |
| SCHEMBL2200118 | 0.82 | MAPK14 (0.55) | MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL2196558 | 0.82 | MAPK14 (0.48) | MAPK14MAPK13MAPK12MAPK11HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060166990-A1 | Novel aminobenzophenone compounds | LEO PHARMA A/S (DK) | 2006-07-27 | — | — | US | claimed |
| US-7977387-B2 | Aminobenzophenone compounds | LEO PHARMA A/S (DK) | 2011-07-12 | — | — | US | disclosed |
| US-7977387-B2 | Aminobenzophenone compounds | LEO PHARMA A/S (DK) | 2011-07-12 | — | — | US | disclosed |
| US-7977387-B2 | Aminobenzophenone compounds | LEO PHARMA A/S (DK) | 2011-07-12 | — | — | US | disclosed |
| US-20060166990-A1 | Novel aminobenzophenone compounds | LEO PHARMA A/S (DK) | 2006-07-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060166990-A1 | Novel aminobenzophenone compounds | NFKBIA, UACA, ALDH7A1 | MAPK14 697/4885MAPK13 1063/4885MAPK12 955/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.